Genticel Inks Over $20m Led by Wellington
Genticel, a biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV), has raised 18.2 million euros ($23.7 million) in additional capital. Wellington Partners led the round which included all current institutional investors IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), InnoBio fund*, IRDI and Amundi Private Equity Funds.
24 April 2013•4 mins read
